Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On December 13, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the fourth quarter and full fiscal year 2024 that ended September 30, 2024 and provided a business update.</li><li>The company is continuing to advance its pipeline, which includes EB06, and anti-CXCL10 monoclonal antibody for the treatment of vitiligo, EB05 for the treatment of acute respiratory distress syndrome (ARDS) and pulmonary fibrosis, and EB01 for the treatment of allergic contact dermatitis (ACD).</li><li>We anticipate an IND being filed before the end of 2025 for EB06 such that a Phase 2 clinical trial can initiate in 2026.</li></ul>

On December 13, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the fourth quarter and full fiscal year 2024 that ended September 30, 2024 and provided a business update.The company is continuing to advance its pipeline, which includes EB06, and anti-CXCL10 monoclonal antibody for the treatment of vitiligo, EB05 for the treatment of acute respiratory distress syndrome (ARDS) and pulmonary fibrosis, and EB01 for the treatment of allergic contact dermatitis (ACD).We anticipate an IND being filed before the end of 2025 for EB06 such that a Phase 2 clinical trial can initiate in 2026.

EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo 